Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19809477&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Progress in therapeutic antisense applications for neuromuscular disorders Aartsma-Rus A; van Ommen GJEur J Hum Genet 2010[Feb]; 18 (2): 146-53Neuromuscular disorders are a frequent cause of chronic disability in man. They often result from mutations in single genes and are thus, in principle, well suited for gene therapy. However, the tissues involved (muscle and the central nervous system) are post-mitotic, which poses a challenge for most viral vectors. In some cases, alternative approaches may use small molecules, for example, antisense oligonucleotides (AONs). These do not deliver a new gene, but rather modulate existing gene products or alter the utilization of pathways. For Duchenne muscular dystrophy, this approach is in early phase clinical trials, and for two other common neuromuscular disorders (spinal muscular atrophy and myotonic dystrophy), significant preclinical advances have recently been made.|*Genetic Therapy/methods[MESH]|Animals[MESH]|Dystrophin/genetics[MESH]|Europe/epidemiology[MESH]|Exons/genetics[MESH]|Genetic Vectors[MESH]|Humans[MESH]|Introns/genetics[MESH]|Male[MESH]|Mice[MESH]|Models, Animal[MESH]|Muscular Atrophy, Spinal/drug therapy/genetics[MESH]|Muscular Dystrophy, Duchenne/drug therapy/genetics/pathology[MESH]|Mutation[MESH]|Myotonic Dystrophy/drug therapy/genetics[MESH]|Neuromuscular Diseases/*drug therapy/epidemiology/*genetics/mortality[MESH]|Oligonucleotides, Antisense/genetics/*therapeutic use[MESH]|RNA Precursors/genetics[MESH]|Transcription, Genetic[MESH] |
